Cargando…
Advance of Serum Biomarkers and Combined Diagnostic Panels in Nonalcoholic Fatty Liver Disease
Nonalcoholic fatty liver disease (NAFLD) affects approximately 25-30% population worldwide, which progresses from simple steatosis to nonalcoholic steatohepatitis (NASH), fibrosis, cirrhosis, and hepatocellular carcinoma, and has complications such as cardiovascular events. Liver biopsy is still the...
Autores principales: | Zeng, Yuping, He, He, An, Zhenmei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9259243/ https://www.ncbi.nlm.nih.gov/pubmed/35811662 http://dx.doi.org/10.1155/2022/1254014 |
Ejemplares similares
-
Advances in Noninvasive Biomarkers for Nonalcoholic Fatty Liver Disease
por: Gîlcă-Blanariu, Georgiana-Emmanuela, et al.
Publicado: (2023) -
Nonalcoholic fatty liver disease: Diagnostic biomarkers
por: Hadizadeh, Fatemeh, et al.
Publicado: (2017) -
Diagnostic Value of CK-18, FGF-21, and Related Biomarker Panel in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis
por: He, Lei, et al.
Publicado: (2017) -
Promising diagnostic biomarkers of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: From clinical proteomics to microbiome
por: Castillo-Castro, Carolina, et al.
Publicado: (2021) -
A Pilot Study of Serum MicroRNAs Panel as Potential Biomarkers for Diagnosis of Nonalcoholic Fatty Liver Disease
por: Tan, Youwen, et al.
Publicado: (2014)